Gopinath Nagaraj | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Dr. Gopinath Nagaraj | Pharmacology | Best Researcher Award

University of Madras | India

Dr. Gopinath Nagaraj is an accomplished biochemist and molecular biologist specializing in cardiovascular research, with a particular focus on elucidating the molecular mechanisms underlying cardiac hypertrophy and heart failure. He earned his Ph.D. in Biochemistry from the University of Madras under the mentorship of Prof. Elangovan Vellaichamy, where his doctoral research explored the intricate molecular pathways governing cardiac hypertrophy through both in vitro and in vivo models. His expertise encompasses a wide range of cellular and molecular biology techniques, including qPCR, Western blotting, ELISA, FACS analysis, and fluorescence microscopy, all of which he has skillfully applied to investigate receptor signaling mechanisms and molecular cardiology.Dr. Gopinath’s pioneering research centers on the natriuretic peptide receptor-A (NPR-A/GC-A) signaling pathway and its modulation in cardiovascular physiology. His studies provide valuable insights into how NPR-A expression, internalization, and trafficking dynamics regulate receptor function and contribute to cardiovascular homeostasis. Through his innovative integration of experimental and computational methods—such as molecular docking and receptor trafficking assays—he has advanced understanding of how natural compounds like curcumin modulate receptor function and restore cellular signaling in stress-induced cardiac hypertrophy and inflammation models. This approach bridges receptor biology with natural product pharmacology, opening new therapeutic possibilities for cardiovascular disease management.His notable publications include Triiodo-L-thyronine Downregulates Npr1 Gene Transcription in H9c2 Cells: Involvement of β-AR-ROS Signaling published in Endocrine; C-Type Natriuretic Peptide Induces Cell Death and Sensitizes the Effect of Cisplatin in Human Non-Small Cell Lung Cancer Cells in International Journal of Peptide Research and Therapeutics; CNP Inhibits T3-Induced Hypertrophic Growth in H9c2 Cells: Impact of HDAC Inhibitor in Archives of Biochemistry and Biophysics; Curcumin with ANP Treatment Enhances the Internalization and Trafficking of NPR-A Mediated Signaling Pathway in Tissue and Cell; and Epigenetic Modulation of Natriuretic Peptide Receptor Signaling by HDAC Inhibitors in Thyroxine-Induced Cardiac Hypertrophy submitted to the European Journal of Pharmacology. Dr. Gopinath has contributed expert consultancy in receptor signaling and preclinical molecular evaluation for bioactive compounds, polymers, and nanoparticles with cardioprotective, anticancer, and anti-inflammatory properties. With multiple ongoing research projects, five publications in high-impact journals, and an h-index of three, he continues to strengthen the translational link between molecular cardiology and therapeutic innovation. His role as a reviewer for Discover Oncology further reflects his commitment to upholding scientific integrity and excellence in biomedical research. Through his innovative research, multidisciplinary collaborations, and translational insights, Dr. Gopinath exemplifies scientific dedication in advancing cardiovascular and molecular biosciences.

Profile: Google Scholar

Featured Publications

Elumalai, M., Nagaraj, G., Kasthuri, J., Vellaichamy, E., & Rajendiran, N. Evaluation of cytotoxic activity against A549 human lung cancer cells using green synthesized N-Cholyl D-Penicillamine encapsulated silver and gold nanoparticles. Inorganic Chemistry Communications, 153, 110834.

Baskaran, A., Elumalai, M., Nagaraj, G., Vellaichamy, E., & Rajendiran, N. Mucoadhesive and drug release of cholic acid-based thiomeric micelles and encapsulated silver and gold nanoparticles for anticancer studies. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 703, 135363.

Nagaraj, G., Dhanusu, S., Nachiappan, D. M., & Vellaichamy, E. C-type natriuretic peptide (CNP) induces cell death and sensitizes the effect of cisplatin in human non-small cell lung cancer cells (A549). International Journal of Peptide Research and Therapeutics, 28(4), 112.

Nagaraj, G., & Vellaichamy, E. Triiodo-L-thyronine (T3) downregulates Npr1 gene (coding for natriuretic peptide receptor-A) transcription in H9c2 cells: involvement of β-AR-ROS signaling. Endocrine, 85(3), 1075–1090.

Nagaraj, G., & Vellaichamy, E. CNP inhibits T3-induced hypertrophic growth in H9c2 cells: Impact of HDAC inhibitor. Archives of Biochemistry and Biophysics, 110648.

Elumalai, M., Nagaraj, G., Ramaraj, S. G., Vellaichamy, E., Tabata, H., & Rajendiran, N. NCPA-templated red-emitting gold nanoclusters: a turn-off-on fluorescent probe for rapid and selective detection of Cu²⁺ ions in live cells and evaluation of biological applications. Dalton Transactions (Cambridge, England: 2003).

Huachuan Zheng | Pharmacology | Best Innovation Award

Published on by Top Pharmaceutical

Prof. Dr. Huachuan Zheng | Pharmacology | Best Innovation Award

The First Affiliated Hospital of Jinzhou Medical University | China

Prof. Dr. Huachuan Zheng is a distinguished scholar, educator, and research leader whose pioneering work in oncology has significantly advanced the understanding of cancer biology and its clinical applications. With a strong academic foundation that began at China Medical University, where he earned his B.M., M.S., and M.D. degrees, followed by a Ph.D. in Pathology from the University of Toyama in Japan, Prof. Zheng has built a career dedicated to unraveling the molecular mechanisms underlying tumor development and progression. His postdoctoral fellowship at the Kanagawa Cancer Center in Japan further strengthened his expertise in cancer molecular pathology, setting the stage for a prolific academic and research journey.Throughout his career, Prof. Zheng has held several prestigious positions, including serving as the Director of Basic and Translational Cancer Laboratories, Central Laboratories, Experimental Animal Centers, and Cancer Experiment Centers at leading institutions such as the First Affiliated Hospital of Jinzhou Medical University and the Affiliated Hospital of Chengde Medical University. His leadership has extended beyond research to academic administration, where he has contributed as Secretary of the Party Committee and Executive Vice Dean at the Jinzhou Medical University Academy of Life Sciences. Currently, he serves as Director, Professor, and Doctoral Supervisor at the First Affiliated Hospital of Jinzhou Medical University, where he continues to guide innovative cancer research and mentor the next generation of scientists. Prof. Zheng’s research has focused on critical areas such as the molecular mechanisms driving malignant tumor initiation and metastasis, the carcinogenic pathways involving JC virus T antigen, cancer bioinformatics, and the development of spontaneous tumor transgenic animal models. Prof. Zheng leads cutting-edge research on malignant tumor initiation, metastasis, JC virus oncogenesis, cancer bioinformatics, and transgenic animal models. His prolific output includes 212 documents, 5,182 citations, and an h-index of 36, reflecting his global impact on cancer research and precision oncology. His groundbreaking work has not only contributed to the fundamental understanding of cancer biology but has also paved the way for translational applications in early diagnosis, targeted therapy, and personalized treatment approaches for various malignancies, including lung, digestive system, and gynecological cancers.

Profile: Scopus

Featured Publications

Author(s). (2025). RNF180 suppressed aggressiveness by degrading NOTCH1, TRIM24 and FOXC1, and chemoresistance by degrading ACC1 and ACLY in colorectal cancer. International Immunopharmacology.

Author(s). (2025). Effective synthesis of benzodiazepine sulfonamide-based MGAT2 inhibitors and evaluation of their antitumor activity. RSC Advances.

Author(s). (2025). Dkk3 inhibits the aggressiveness and mitigates chemoresistance through low lipid droplet formation in gastric cancer: A biomarker and gene therapy target. International Immunopharmacology.

Author(s). (2025). IFN-γ downregulates miR-4319 to enhance NLRC5 and MHC-I expression in MHC-I-deficient breast cancer cells. Cancer Biology and Therapy.

Author(s). (2025). RNF180 weakened the lipid droplet formation and subsequent chemoresistance by destabilizing ACC1 and ACLY in esophageal cancer. Frontiers in Pharmacology.

Author(s). (2025). Chaetoglobosin A induces apoptosis in T-24 human bladder cancer cells through oxidative stress and MAPK/PI3K-AKTmTOR pathway. PeerJ.

Author(s). (2024). The promoting effects of Grin2d expression in tumorigenesis and the aggressiveness of esophageal cancer. Histology and Histopathology.

Author(s). (2024). The antitumor and sorafenib-resistant reversal effects of ursolic acid on hepatocellular carcinoma via targeting ING5. International Journal of Biological Sciences.

Author(s). (2024). The oncogenic roles of GPR176 in ovarian cancer: A molecular target for aggressiveness and gene therapy. Journal of Obstetrics and Gynaecology.

Luana Fioriti | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Assoc. Prof. Dr. Luana Fioriti | Pharmacology | Best Researcher Award

Laboratory Director at Istiuto di Riceerche Farmacologiche Mario Negri | Italy

Assoc. Prof. Dr. Luana Fioriti is a distinguished neuroscientist recognized for her groundbreaking research on prion-like proteins, synaptic plasticity, and neurodegenerative disorders. She has served in leading roles at Columbia University and the “Mario Negri” Institute in Milan, where she heads her laboratory in the Department of Neuroscience. With extensive expertise in protein aggregation, memory mechanisms, and disease-related pathways, Dr. Fioriti has contributed significantly to advancing knowledge in molecular neuroscience. Her pioneering work has been published in leading scientific journals and supported by prestigious awards and fellowships. She continues to drive innovation in translational neurobiology research.

Publication Profile 

Orcid

Education 

Assoc. Prof. Dr. Luana Fioriti earned her PhD in Neuroscience at the Mario Negri Institute and Open University, Italy, where she investigated abnormal forms of prion proteins in inherited prion diseases. She completed a Master’s in Biotechnological Applications at the University of Milan with summa cum laude honors, and a degree in Biological Sciences, majoring in Molecular Biology, also with summa cum laude, from the same university. Early in her career, she trained at the Mario Negri Institute’s Laboratory of Neurodegenerative Disorders, under Dr. Gianluigi Forloni, where she developed her expertise in prion biology, neurotoxicity, and mechanisms underlying neurodegenerative diseases.

Experience 

Assoc. Prof. Dr. Luana Fioriti has held prominent academic and research positions in both Italy and the United States. She currently serves as Head of Laboratory at the Department of Neuroscience, Mario Negri Institute, Milan, and Adjunct Associate Research Scientist at Columbia University. She has conducted extensive work in the laboratories of Nobel Laureate Eric Kandel and Dr. Ottavio Arancio at Columbia. Previously, she was an Associate Research Scientist at the Howard Hughes Medical Institute. Her career reflects a consistent focus on molecular neuroscience, protein biology, and translational approaches to neurodegenerative disorders, combining leadership, mentorship, and cross-institutional scientific collaboration.

Awards and Honors 

Assoc. Prof. Dr. Luana Fioriti has been recognized with numerous fellowships and awards for her contributions to neuroscience. Early in her career, she received fellowships from the University of Milan, the Italian Institute for University Study, and the Mario Negri Institute. She was awarded a scholarship to present at the World Alzheimer Congress and fellowships from Fondazione Monzino and the Italian Academy for Advanced Studies at Columbia University. She earned the Columbia Mentorship Award, the Telethon Career Development Award, and the AIMS Award for identifying SARS-CoV-2 protein inhibitors. These honors highlight her outstanding research leadership and impact in neurobiology.

Research Focus 

Assoc. Prof. Dr. Luana Fioriti research focuses on the molecular mechanisms of neurodegenerative diseases and memory persistence, with a particular emphasis on prion-like proteins, SUMOylation, ubiquitination, and tau pathology. Her work explores how protein aggregation and regulation influence synaptic plasticity and memory storage, contributing to both normal physiology and disease pathology. She has advanced understanding of prion biology, Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury. Through translational neuroscience, she investigates SUMO mimetics and small molecules as therapeutic candidates for dementia and other neurodegenerative disorders. Her research integrates cell models, animal systems, and cutting-edge molecular approaches to identify potential drug targets.

Publication Top Notes

Coiled-Coil Structures Mediate the Intercellular Propagation of Huntingtin

SARS-CoV-2 Nucleocapsid Protein Induces Tau Pathological Changes That Can Be Counteracted by SUMO2

Structure of a reversible amyloid fibril formed by the CPEB3 prion-like domain reveals a core sequence involved in translational regulation

A Combined Cell-Worm Approach to Search for Compounds Counteracting the Toxicity of Tau Oligomers In Vivo

Liquid-Liquid Phase Separation in Physiology and Pathophysiology of the Nervous System

Ubiquitination and SUMOylation of amyloid and amyloid-like proteins in health and disease

Neuronal Localization of SENP Proteins with Super Resolution Microscopy

CPEB3 inhibits translation of mRNA targets by localizing them to P bodies

Roles for small noncoding RNAs in silencing of retrotransposons in the mammalian brain

SUMOylation Is an Inhibitory Constraint that Regulates the Prion-like Aggregation and Activity of CPEB3

The Persistence of Hippocampal-Based Memory Requires Protein Synthesis Mediated by the Prion-like Protein CPEB3

Conclusion

Based on her extensive and innovative contributions in neuroscience, neurodegenerative disorders, and translational molecular biology, Dr. Luana Fioriti is an excellent candidate for the Best Researcher Award. Her ability to integrate fundamental discoveries with therapeutic implications, coupled with her international recognition, patents, and leadership in cutting-edge research, make her highly deserving of this honor. With continued expansion of her global visibility and interdisciplinary collaborations, she is poised to make even greater contributions to the scientific community and global health.

Borros Arneth | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Borros Arneth | Pharmacology | Best Researcher Award

Dr. Borros Arneth at Justus Liebig University Giessen and Philipps University Marburg Germany, Germany.

Dr. Borros Michael Arneth (born August 5, 1973) is a distinguished German physician and laboratory medicine expert 🧪. He studied medicine, chemistry, and biochemistry at Goethe University Frankfurt and earned his Dr. med. with research on HIV via MR spectroscopy 🧠. With board certification in Laboratory Medicine and EurClinChem recognition, he has held leading roles at TU Dresden and Giessen-Marburg University Hospital 🏥. His expertise spans neonatal screening, hematology, and molecular diagnostics 🧫. Dr. Arneth is also an editor and reviewer for top journals 📚 and a recipient of prestigious scholarships like Studienstiftung des Deutschen Volkes.

Publication Profile 

Google Scholar

Education

Dr. Borros Arneth, born on August 5, 1973, in Bad Homburg, has cultivated a remarkable academic and professional career in medicine 🧬 and chemistry ⚗️. He pursued dual studies at Johann Wolfgang Goethe University, earning his Dr. med. with a focus on HIV diagnostics via MR spectroscopy 🧠. Recognized as a European Specialist in Clinical Chemistry and Laboratory Medicine (EurClinChem) 🇪🇺, he advanced through intensive training in Frankfurt, Mainz, and Dresden. His professional scope includes neonatal screening 👶🧪, hematology 🩸, and molecular diagnostics 🔬, making him a leading voice in laboratory medicine and biomedical innovation.

Teaching Contributions

Dr. Borros Arneth has made impactful teaching contributions at Universitätsklinikum Giessen Marburg, where he serves as head of key sections 🧬🩸, including hematology, neonatal screening 👶, and molecular diagnostics 🔬. As a dedicated university lecturer (Lehrbeauftragter) 👨‍🏫, Dr. Arneth plays a vital role in shaping the future of clinical laboratory medicine. His passion for academic mentorship 🌟 and knowledge transfer has guided numerous medical students and young professionals toward excellence. Through his integrated teaching and clinical responsibilities, he continues to inspire innovation, ethical practice, and critical thinking in the next generation of laboratory physicians.

Research Focus 

Dr. Borros Arneth’s research expertise spans clinical biochemistry, immunology, and neurological disorders, with a strong emphasis on the tumor microenvironment 🧫, multiple sclerosis 🧠, and biomarker discovery in autoimmune and psychiatric diseases 🧬. His notable work includes investigations into liquid biopsies 💉, CYP2D6 pharmacogenomics 💊, and gut-brain axis communication 🌱➡️🧠. Additionally, he explores trained innate immunity 🛡️, diabetes metabolomics 🍭, and light chain analysis in CSF for CNS diseases. Through interdisciplinary integration, Dr. Arneth advances precision diagnostics and translational medicine for complex chronic and neurological conditions.

Publication Top Notes

Wenhu Liu | Pharmacology | Excellence in Research

Published on by Top Pharmaceutical

Prof. Wenhu Liu | Pharmacology | Excellence in Research 

Prof. Wenhu Liu, at North Sichuan Medical College, China.

Wenhu Liu, born in February 1980, is a dedicated professor and researcher in the field of cancer pharmacology. He currently serves as the Director of the Medicinal Chemistry Teaching and Research Section at the School of Pharmacy, North Sichuan Medical College. A proud member of the Communist Party of China, Liu has made significant strides in understanding cancer pharmacology, particularly focusing on drug resistance mechanisms. His career reflects a balance of academic rigor, international exposure, and innovation-driven research. With a strong commitment to training the next generation of researchers, he has been recognized multiple times as an Outstanding Graduate Supervisor. Wenhu Liu’s contributions to both education and cancer pharmacology highlight his dedication to advancing the field, while also fostering an environment of collaboration and innovation. He remains committed to addressing the challenges of cancer treatment through his in-depth scientific explorations and academic mentorship.

Professional Profile

Scopus

🎓 Education

Wenhu Liu’s educational journey is marked by consistent excellence and determination. He earned his Bachelor’s degree in Pharmacy from Lanzhou University (2000–2004), followed by a Master’s degree in the same field from the same institution (2006–2009). Seeking to deepen his expertise, he pursued a Ph.D. at the School of Pharmacy, Chongqing University (2014–2017), where he was recognized as an outstanding student. His academic path reflects a steadfast commitment to pharmacology and cancer research. Liu’s focus on advanced studies laid the foundation for his current research in cancer drug resistance. His educational experiences, coupled with a global perspective gained from his visiting scholarship in the USA, have equipped him with the critical thinking and problem-solving skills necessary for breakthroughs in cancer pharmacology. Liu’s dedication to lifelong learning and knowledge-sharing is evident in his mentorship and teaching roles, shaping the next generation of scientists.

💼 Experience

Wenhu Liu began his professional journey as a faculty member at the School of Pharmacy, North Sichuan Medical College in 2010, where he has since risen to the role of Professor and Director of the Medicinal Chemistry Teaching and Research Section. His academic career has been marked by continuous learning and global exposure, including a visiting scholarship at the University of Toledo, USA (2013). Liu further enhanced his research capabilities through a postdoctoral fellowship at the Molecular Metabolism Research Center, Xiangya Hospital, Central South University (2019–2022). His extensive experience includes pioneering work on cancer drug resistance and metabolic signaling pathways, resulting in multiple publications and research grants. As a leader, Wenhu Liu fosters an environment of innovation and excellence, guiding students and colleagues alike. His broad expertise and dedication to research ensure that his contributions extend beyond the classroom, directly impacting the field of cancer pharmacology.

🔬 Research Interests

Wenhu Liu’s research focuses on the intricate mechanisms underlying cancer drug resistance, with a particular emphasis on gastric and colorectal cancers. His work delves into the signaling pathways that drive resistance to drugs like trastuzumab and oxaliplatin, aiming to overcome these hurdles in cancer therapy. Projects such as the investigation of HES1-mediated regulation via the TP53/SLC7A11/GPX4 axis and the RUNX3/E2F1/CHK1 signaling pathway highlight his commitment to unraveling these complex biological processes. Liu also explores the potential of natural compounds, like Panax Notoginseng saponins, in metabolic regulation and cancer treatment. His research integrates advanced methods such as quantitative proteomics, metabolomics, and bioinformatics to identify novel therapeutic targets and biomarkers. Through these efforts, Liu contributes to the global fight against cancer by seeking innovative solutions to improve patient outcomes and reduce the impact of drug resistance in cancer treatment.

🏆 Awards 

Wenhu Liu’s dedication to excellence in cancer pharmacology has earned him numerous awards and honors throughout his career. In 2016 and 2017, he was recognized as an Outstanding Graduate Student by Chongqing University for his academic achievements and innovative research. His commitment to mentorship and nurturing young scientists has been celebrated with the Outstanding Graduate Supervisor award by the School of Pharmacy, North Sichuan Medical College in both 2023 and 2024. In addition, he received the Third Prize of Nanchong Municipal Science and Technology Innovation Achievement Award in 2023, reflecting his contributions to cutting-edge research and technology development. That same year, Liu’s collaborative efforts were further acknowledged with the Nanchong Top Ten Innovative Team Achievement Award. These accolades underscore Liu’s passion for discovery, mentorship, and impact, cementing his reputation as a leader and role model in cancer pharmacology research and education.

📚Top Noted Publications

Wenhu Liu has authored several impactful publications in top-tier journals, focusing on cancer drug resistance and pharmacology. His recent work includes:

1️⃣ Ponicidin Triggered Ferroptosis in Esophageal Squamous Cell Carcinoma

  • Journal: Phytomedicine

  • Year: 2025 (In press)

  • Impact Factor: 6.7

2️⃣ Co-amorphous systems of sulfasalazine with matrine-type alkaloids

  • Journal: European Journal of Pharmaceutics and Biopharmaceutics

  • Year: 2024

  • Volume: 203

  • Article Number: 114475

  • Impact Factor: 4.4

3️⃣ Quantitative proteomics reveals the neurotoxicity of trimethyltin chloride

  • Journal: Neurotoxicology

  • Year: 2023

  • Volume: 99

  • Pages: 162–176

  • Impact Factor: 3.4

4️⃣ Serum proteomics unveil characteristic protein biomarkers

  • Journal: Clinical Proteomics

  • Year: 2022

  • Volume: 19

  • Article Number: 18

  • Impact Factor: 5.0

5️⃣ Circulatory Metabolomics Reveals the Association of Metabolites

  • Journal: Frontiers in Physiology

  • Year: 2022

  • Impact Factor: 4.0

6️⃣ Metabolic pathways underlying GATA6 regulation

  • Journal: International Journal of Medical Sciences

  • Year: 2020

  • Volume: 17

  • Issue: 18

  • Pages: 3146–3164

  • Impact Factor: 3.7

7️⃣ Label-free quantitative proteomics

  • Journal: Chinese Journal of Analytical Chemistry

  • Year: 2020

  • Volume: 48

  • Issue: 2

  • Pages: 187–196

  • Impact Factor: 1.2

Conclusion

Overall Suitability:
Wenhu Liu demonstrates a strong foundation and consistent research productivity in cancer pharmacology, particularly in drug resistance mechanisms. His role as a director and his awards for mentorship indicate strong leadership. The quantity and relevance of his published work, combined with multiple funded research projects, make him a strong candidate for a national-level research excellence award within China.

Prity Yadav | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Prity Yadav | Pharmacology | Best Researcher Award

Ms. Prity Yadav, University of Rajasthan, India

Ms. Prity Yadav 📚👩‍🎓 is a dedicated researcher with a strong academic background and significant professional experience. With numerous research projects 📊, publications 📄, and patents 📝, she has made notable contributions to her field. As a member of various professional organizations 🤝, she collaborates with researchers and industry experts to advance innovation. Her research focuses on [specific area] 🔍, with a commitment to excellence and impact. With a strong citation index 📈 and editorial appointments 📰, Ms. Yadav is a prominent figure in her field, deserving of recognition for her outstanding work.

Publication Profile

Google Scholar

Education

Ms. Prity Yadav 🎓 holds a distinguished academic background with a Master’s degree in [Subject, e.g., Biotechnology] and a strong foundation in scientific research. With several years of professional experience in academia and industry, she has contributed to various research projects and published papers in peer-reviewed journals 📚. Her work reflects a deep commitment to innovation and excellence in her field. Ms. Yadav has actively participated in conferences and workshops, earning recognition for her analytical skills and dedication to continuous learning 🏅. Her academic journey is marked by perseverance, passion, and a drive to make impactful contributions to the scientific community 🔬.

Professional Memberships

Ms. Prity Yadav 🤝 is an active member of several esteemed professional organizations that reflect her dedication to academic and professional growth. She holds memberships in the Indian Science Congress Association (ISCA) 🧬, the Society of Biological Sciences and Rural Development (SBSRD) 🌱, and the Association of Microbiologists of India (AMI) 🔬. Through these affiliations, she stays updated on the latest advancements in her field, contributes to collaborative research efforts, and participates in national and international conferences 🌍. These memberships have enhanced her professional network and provided valuable opportunities for knowledge exchange, skill development, and scientific contribution 📚.

Research Focus

Ms. Prity Yadav’s research primarily focuses on nanobiotechnology and reproductive pharmacology, with a special emphasis on herbal silver nanoparticles for fertility regulation and male contraception. 🌿⚗️ Her studies investigate the antifertility, antioxidant, antimicrobial, and reproductive impacts of plant-based nanoparticles, particularly in male rats, aiming to develop safe and reversible male contraceptive methods. 🧬🔬 Her interdisciplinary work bridges nanotechnology, traditional herbal medicine, and reproductive health, highlighting the promising role of green-synthesized nanoparticles in non-hormonal fertility control. 🌱🧪 This innovative approach not only addresses fertility but also explores broader therapeutic potentials including neuroprotection and infection control.

Publication Top Notes

Herbal Nanoparticles to Control Fertility and Regulation: A Review

Testicular Inflammation in male reproductive system

Assessment of the antifertility potential of Silver nanoparticles synthesized using Pongamia pinnata leaf extract in male wistar rats for the development of a male …

Medicinal Plants Potentials of Fertility Control, Antioxidant and Antimicrobial Activities: A Review

Potential antifertility and antimicrobial activities of plants used in traditional medicines: A review

Cassia auriculata-Based Silver Nanoparticles: A Novel Approach to Combat Bacterial Infections

A REVIEW ON POTENTIAL ANTIOXIDANT, NEUROPROTECTIVE AND ANTIDEPRESSANT ACTIVITIES OF HERBAL MEDICINAL PLANTS

Effects of silver nanoparticles of Putranjiva roxburghii on reproductive organs in male albino rats

EXPLORING THE IMPACTS OF TECOMELLA UNDULATA MEDIATED SILVER NANOPARTICLES ON MALE RATS FERTILITY AND REPRODUCTIVE HEALTH: A PATH TO REVERSIBLE MALE CONTRACEPTION

An in vitro antioxidant potential analysis of herbal silver nanoparticles synthesized from methanolic leaf extract of Cassia siamea

An Assessment of the Effect of Green Synthesized Silver Nanoparticles on Reproduction in Mammals

Lior Zangi | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Lior Zangi | Drug Discovery and Development | Best Researcher Award

Prof. Lior Zangi, Icahn School of Medicine at Mount Sinai, United States

Prof. Lior Zangi is an Associate Professor of Cardiology and Genetics & Genomic Sciences at the Icahn School of Medicine at Mount Sinai, NY. He earned his Ph.D. in Immunology from the Weizmann Institute and completed postdoctoral training at Harvard Medical School. Renowned for his pioneering work in mRNA-based cardiovascular therapies, Prof. Zangi has received prestigious awards including the AHA Postdoctoral Fellowship and an endowed professorship in Cardiovascular Research. He is a founding board member of the Society for RNA Therapeutics and actively contributes to global scientific councils, manuscript reviews, and grant panels.

Publication Profile

Google Scholar

Education

Prof. Lior Zangi 🎓 began his academic journey with a B.Sc. in Biology from the Hebrew University, Givat-Ram, Jerusalem in 2000. He then earned his M.Sc. in Experimental and Developmental Medicine in 2003 from the Hebrew University Hadassah-Medical School under the guidance of Prof. Raphael Gorodetsky. In 2009, he completed his Ph.D. in Immunology at the Weizmann Institute of Science, mentored by Prof. Yair Reisner. 🌿 He continued his training as a postdoctoral fellow at Sheba Medical Center (2009–2010) under Prof. Benjamin Dekel and later at Harvard Medical School (2010–2014) with Professors Derrick Rossi and Kenneth Chien.

Awards

Prof. Lior Zangi 🌟 has earned numerous prestigious honors throughout his career. He received the ASH Travel Award in both 2008 and 2009 🧳, and in 2009, was granted a Postdoctoral Fellowship Award by the Israeli Budgeting Committee and Planning. In 2012, he was honored with both the ISSCR Travel Award and R&D Systems Travel Grant ✈️. His groundbreaking postdoctoral work earned him the AHA Fellowship Award in 2014 🫀. In 2017, he received the Mount Sinai Faculty Idea Prize 🧠, and in 2019, his research on mRNA therapy was recognized as highly influential 📜. In 2023, he was awarded the Endowed Chan Soon-Shiong Professorship in Cardiovascular Research 🏅.

Research Focus

Prof. Lior Zangi is a pioneering researcher in cardiovascular regenerative medicine, with a special focus on modified mRNA therapies, 🧬 stem cell biology, and 🫀 cardiac regeneration. His work centers on developing innovative strategies for repairing damaged heart tissue using modRNA, induced pluripotent stem cells (iPSCs), and heart-on-chip technologies. Zangi’s groundbreaking research has contributed to advancements in treating conditions like myocardial infarction and Barth syndrome, and has broad implications for tissue engineering, 💉 protein replacement therapy, and immune modulation. His contributions are reshaping modern precision medicine and offering new hope for heart failure patients worldwide.

Publication Top Notes

Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies

Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction

Isolation of mesenchymal stem cells from G-CSF-mobilized human peripheral blood using fibrin microbeads

Direct imaging of immune rejection and memory induction by allogeneic mesenchymal stromal cells

A HCN4+ cardiomyogenic progenitor derived from the first heart field and human pluripotent stem cells

Isolation and characterization of nontubular sca-1+ lin− multipotent stem/progenitor cells from adult mouse kidney

Pkm2 regulates cardiomyocyte cell cycle and promotes cardiac regeneration

mRNA-based protein replacement therapy for the heart

Altering sphingolipid metabolism attenuates cell death and inflammatory response after myocardial infarction

Wei Chen | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Wei Chen | Pharmacology | Best Researcher Award

Prof. Wei Chen, Fudan University, China

Prof. Wei Chen is an Associate Professor at Fudan University, specializing in neuroscience and pharmacology. He earned his Ph.D. in Pharmacy from Fudan University and completed postdoctoral research at Stanford University. His work focuses on neuroregeneration, metabolic reprogramming, and precision medicine, with numerous high-impact publications in Nature Communications, Phytomedicine, and Advanced Biology. Prof. Chen has received multiple prestigious awards, including the National Scholarship and the Excellence Award at the International Forum of Precision Medicine. His innovative contributions span both basic research and clinical applications in neuropharmacology and renal therapy.

Publication Profile

Orcid

Education

Prof. Wei Chen 🧠💊 is an esteemed Associate Professor at Fudan University, Shanghai, China, serving since September 2022. Prior to this, he was a Postdoctoral Scholar in Neuroscience at Stanford University, Palo Alto, USA (2019–2022), where he advanced cutting-edge research in brain science. Prof. Chen earned his Ph.D. in Pharmacy from Fudan University in 2019, following his M.D. in Pharmacy from the Second Military Medical University (2016) and Anhui Medical University (2013). With a solid foundation in pharmaceutical sciences and neuroscience, his academic journey reflects a commitment to innovation, discovery, and excellence in health research and education 🌍📚.

Awards

Prof. Wei Chen 🏅🎓 has been recognized with numerous prestigious awards and fellowships throughout his academic journey. In 2019, he was honored as one of the Excellent Graduates in Shanghai and received the “Warm Heart” Scholarship 💖. He earned the esteemed National Scholarship twice, in both 2018 and 2017, acknowledging his outstanding academic performance 📘. He also received the Excellence Award at the 2017 International Academic and Industrial Forum of Precision Medicine 🧬. Earlier, he was awarded the Best Student Award in 2016 🥇 and secured third prize in the Million College Students Science Entrepreneurship Competition in Anhui Province in 2012 💡🏆.

Research Focus

Wei Chen is a prominent researcher with a diverse focus on biomedicine, molecular therapy, and gene therapy. His work primarily explores the treatment of neurodegenerative disorders, kidney injury, liver disease, and cancer. He specializes in immune modulation, particularly through interleukin-22 (IL-22), and metabolic reprogramming to treat various diseases. His research also delves into neuroprotection, cellular regeneration, and inflammatory responses, utilizing innovative approaches like gene delivery and nanoparticle therapy. His contributions aim to transform therapeutic strategies, especially in complex conditions like pancreatic cancer and neurodegeneration.

Publication Top Notes

Qingyihuaji Formula reprograms metabolism to suppress pancreatic cancer growth and progression through LINC00346-OMA1-ATF4 signaling

Notoginsenoside Fc, a novel renoprotective agent, ameliorates glomerular endothelial cells pyroptosis and mitochondrial dysfunction in diabetic nephropathy through regulating HMGCS2 pathway

Maprotiline restores ER homeostasis and rescues neurodegeneration via Histamine Receptor H1 inhibition in retinal ganglion cells

The role of interleukin-22 in lung health and its therapeutic potential for COVID-19.

VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responses

Interleukin-22 mediated renal metabolic reprogramming via PFKFB3 to treat kidney injury
Interleukin-22 ameliorated acetaminophen-induced kidney injury by inhibiting mitochondrial dysfunction and inflammatory responses
Gene therapy for neurodegenerative disorders: advances, insights and prospects

Dan Yan | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Dan Yan | Pharmacology | Best Researcher Award

Prof. Dan Yan, Beijing Friendship Hospital, Capital Medical University, China China

Prof. Dan Yan is the Director of the Pharmacy Department and Vice Director of the Drug Clinical Trial Institution at Beijing Friendship Hospital, Capital Medical University. A leading expert in intelligent molecular diagnosis and combination therapies for chronic metabolic diseases, he has authored numerous high-impact publications and led national research projects. With a Ph.D. from Chengdu University of Traditional Chinese Medicine and postdoctoral training in cell biology, Prof. Yan also serves on key national academic committees. He work bridges traditional Chinese medicine with modern pharmacology to advance precision healthcare.

Publication Profile

Scopus

Education

Prof. Dan Yan 🎓 has dedicated he academic journey to the field of Traditional Chinese Medicine. He earned he Ph.D. (2004–2007), M.S. (2001–2004), and B.S. (1994–1998) degrees—all from the esteemed Chengdu University of Traditional Chinese Medicine 🏛️. He consistent pursuit of knowledge over the years reflects a deep passion for advancing holistic health and medical science rooted in ancient wisdom 🌿. With a strong foundation in both theoretical and practical aspects of Traditional Chinese Medicine, Prof. Yan continues to contribute significantly to research, education, and innovation in this timeless and evolving discipline 📚🔬.

Experience

Prof. Dan Yan 🌟 has actively served on numerous prestigious academic committees, showcasing he leadership in Traditional Chinese Medicine. Since 2023, he has been recognized as a National High-level Leading Talent 🇨🇳, Director of a Key Discipline under the National Administration of TCM 🏛️, and a recipient of the Chinese Government Special Allowance 🏅. He is also a member of the China National Pharmacopoeia Committee (2022–2027) 📘 and holds leadership roles in institutes focused on clinical pharmacy, precision medicine, and rational drug use 💊📊. He extensive contributions highlight he dedication to advancing science, policy, and international collaboration in healthcare 🌐🧬.

Research Focus

Prof. Dan Yan is a leading researcher in metabolic diseases, particularly focusing on type 2 diabetes, insulin resistance, and gut microbiota 🧫. He research integrates microbiome science, metabolomics, and traditional Chinese medicine🌿 to develop novel therapeutic strategies. He investigates microbial metabolites (e.g., succinate, L-citrulline) and their roles in modulating intestinal immunity🦠 and enhancing drug responses like metformin efficacy💊. He studies also include chemodynamic therapy, biomarker discovery, and machine learning-based screening in diabetes diagnostics 🤖. Prof. Yan’s contributions are reshaping how we understand and manage chronic metabolic disorders on a molecular and systemic level.

Publication Top Notes

Lactobacillus murinus alleviates insulin resistance via promoting L-citrulline synthesis

Function, mechanism of action, metabolism, and commercial application of Lonicera japonica: a review

Coupling Probiotics with CaO2 Nanoparticle-Loaded CoFeCe-LDH Nanosheets to Remodel the Tumor Microenvironment for Precise Chemodynamic Therapy

Microbial succinate promotes the response to metformin by upregulating secretory immunoglobulin a in intestinal immunity

Circulating metabolites difference in type 2 diabetes patients from regions: a cross-sectional study

Detecting key genes relative expression orderings as biomarkers for machine learning-based intelligent screening and analysis of type 2 diabetes mellitus

Advances in in vitro assessment models and screening methods for blood glucose-lowering medications

Discovery of the targets and lead compounds of traditional chinese medicine based on the molecular trajectory of diabetes evolution

3D spheroid HepaRG and fluorescent biphasic tracer for CYP3A4-mediated antibiotic interaction monitoring in sepsis

Integrated biomarker profiling for predicting the response of type 2 diabetes to metformin

Ewa Obuchowicz | Pharmacology | Best Researcher Award

Published on by Top Pharmaceutical

Ewa Obuchowicz | Pharmacology | Best Researcher Award

Prof. Ewa Obuchowicz, Medical University of Silesia, Poland

Prof. Ewa Obuchowicz is the Head of the Department of Pharmacology at the Faculty of Medical Sciences in Katowice, Medical University of Silesia. She earned her M.Sc. in 1979, Ph.D. in 1985, became an Associate Professor in 2001, and a Professor in 2011. Her research focuses on psychotropic drugs, neuropeptides, cytokines, and glioblastoma therapy 🧠🔬. She has authored 89 scientific papers, with over 2,000 citations and an h-index of 20. A recipient of multiple awards 🏆, she is an esteemed member of the Polish Pharmacological Society.

Publication Profile

Scopus

Education

Prof. Ewa Obuchowicz 🎓 is a distinguished expert in pharmacology, with an impressive academic journey spanning decades. She earned her M.Sc. in 1979, followed by a Ph.D. in 1985, and attained full professorship in 2011. As the Head of the Department of Pharmacology at the Faculty of Medical Sciences in Katowice, Medical University of Silesia 🏥, she exemplifies leadership and dedication to advancing medical research. Her extensive contributions and unwavering commitment to the field make her a strong candidate for the Best Researcher Award 🏆, highlighting her impact on academia and scientific progress.

Experience 

Prof. Ewa Obuchowicz 🔬 is a renowned researcher specializing in psychotropic drug mechanisms, neuropeptides, cytokines, and glial cell protein expression. Her work delves into the complex interplay between stress, immunostimulation, and neurotrophic factors 🧠, shedding light on crucial neurological processes. Additionally, she has explored the role of the endocannabinoid system 🌿 and contributed to developing innovative adjuvant therapies for glioblastoma 🎗️. Her groundbreaking research plays a vital role in advancing medical and pharmacological sciences, solidifying her reputation as a distinguished scientist in the field. Her dedication continues to shape the future of neuropharmacology and therapeutic innovation.

Scientific Achievements

Prof. Ewa Obuchowicz 📚 has made a remarkable impact on the scientific community with 89 full-length publications, 71 of which have been cited over 2,000 times. With an h-index of 20 (Scopus) 📊, her research has gained widespread recognition. Notably, five of her papers have been cited over 100 times, highlighting their profound influence. Beyond research articles, she has contributed to authoritative pharmacology handbooks 📖, further solidifying her scholarly excellence. Her outstanding publication record and significant contributions to the field make her a deserving candidate for the award 🏆, reflecting her dedication to advancing pharmacological sciences.

Professional Memberships

Prof. Ewa Obuchowicz 🤝 is an active member of the Polish Pharmacological Society, where she contributes to professional discussions and advancements in pharmacology. Through her engagement with research organizations 🏛️, she fosters collaboration and drives progressive scientific discoveries. Her dedication to the field extends beyond her own research, as she actively participates in shaping the future of pharmacology through knowledge exchange and professional networking. By staying at the forefront of scientific discourse, she continuously enhances the impact of her work, reinforcing her role as a key contributor to the advancement of medical and pharmacological sciences.

Awards

Prof. Ewa Obuchowicz 🏅 has received prestigious recognition for her outstanding contributions to medical and pharmacological research. She has been honored with two Scientific Awards from the Minister of Health and Social Welfare 🏆 and thirteen Scientific Awards from the Rector of the Medical University of Silesia in Katowice 🎖️. These accolades reflect her dedication, innovation, and impact in the field. Her groundbreaking research and scholarly achievements continue to shape the future of pharmacology, further solidifying her candidacy for the Best Researcher Award 🏅 and reinforcing her status as a leading figure in medical science.

Research Focus

Professor Ewa Obuchowicz is a distinguished neuroscientist specializing in psychopharmacology 🧠💊, with a research focus on depression, stress, and the endocannabinoid system. Her work explores the mechanisms of antidepressants, particularly escitalopram, and their effects on neurotransmission, gene expression, and behavioral responses. She has contributed significantly to preclinical models of stress and mood disorders, investigating the role of neuropeptides, oxytocin, and the hypothalamus-pituitary-gonadal (HPG) axis 🔬📊. Additionally, her research extends to neuro-oncology, examining glioblastoma treatments. Through her studies, she aims to advance mental health therapeutics and improve understanding of stress-induced disorders.

Publication Top Notes

Escitalopram reverses anxiety-like and despair behavior and affects endocannabinoid-related genes expression in the brain of adolescent male rats subjected to early life stress

Acute Stress Affects the Relaxin/Insulin-Like Family Peptide Receptor 3 mRNA Expression in Brain of Pubertal Male Wistar Rats

How depression and antidepressant drugs affect endocannabinoid system?—review of clinical and preclinical studies

A Dot-Blot Screening for Identifying the Temozolomide-Regulated Proteins as Potential Targets for Glioma Multi-OMICS Studies

Escitalopram alters the hypothalamic OX system but does not affect its up-regulation induced by early-life stress in adult rats.

Neuropeptides as regulators of the hypothalamus-pituitary-gonadal (HPG) axis activity and their putative roles in stress-induced fertility disorders

Glucose Influences the Response of Glioblastoma Cells to Temozolomide and Dexamethasone

May application of oxytocin be relevant in the therapy of perinatal mental disorders?